Get started
Work

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival

Year: 2013
Type: article
Abstract: Meeting abstracts Combination immunotherapy is quickly gaining attention in the field of cancer treatment. IL-2, a cytokine which activates T cells, and ipilimumab, a monoclonal antibody that blocks CTLA-4, are both approved as monotherapy for metastatic melanoma. To date, combination immunotherapy
DOI: 10.1186/2051-1426-1-s1-p70
Authors: Joseph R Broucek, Tasha Hughes, Erica J Huelsmann, Joseph L Poshepny, Carl E Ruby, Andrew Zloza, Howard L Kaufman
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W2049052745
FWCI:
Cites:
Cited by:
Related to: 10